jackie.vuistiner

Recruitment completed for denovoSkin™ Phase 2 clinical trial in reconstructive surgery

Switzerland, 07 November – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced the successful completion of patient recruitment for the Phase 2 clinical trial of its lead product, denovoSkin™, in reconstructive surgery for both children and adults. This Phase 2 clinical trial evaluates the safety …

Recruitment completed for denovoSkin™ Phase 2 clinical trial in reconstructive surgery Read More »

Inauguration of CUTISS Innovation

We’re proud to announce the recent inauguration of CUTISS Innovation, the French subsidiary of CUTISS AG, at the renowned Sophia Antipolis technology park in France. CUTISS Innovation is supporting and extending our R&D activities in regenerative medicine, including skin pigmentation, aging and healing. The Provence-Alpes-Côte d’Azur region is renowned as an innovation and dermatology hotspot, …

Inauguration of CUTISS Innovation Read More »

CUTISS launches Series C financing round to advance the development of its personalized skin technology, paving the way towards commercialization

Switzerland, 18 September 2023 – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced the launch of its Series C for the next stage of the company’s development. CUTISS seeks to raise the Series C with the participation of existing and new investors to take its personalized skin …

CUTISS launches Series C financing round to advance the development of its personalized skin technology, paving the way towards commercialization Read More »

GEN interview

Genetic Engineering & Biotechnology News (GEN), the leading life sciences publication, recently interviewed our CEO Daniela Marino. The article reports on CUTISS’s progress with denovoSkin™ and the clinical trials, how the company plans to restore patients’ own skin pigmentation, the key role of automation to meet the scale up challenge, and CUTISS’s global ambitions. “The product …

GEN interview Read More »

CUTISS awarded CHF 2.5M grant for automation program

CUTISS is delighted to announce that Innosuisse, the Swiss Innovation Agency, has awarded the company a CHF 2.5 million grant to advance our pioneering automation program. This grant will support the industrialization of denovoCast™, the world’s first machine that can bio-engineer large, personalized skin tissue grafts, in a fully closed way. This is yet another …

CUTISS awarded CHF 2.5M grant for automation program Read More »

CUTISS announces positive Phase 2 clinical trial results for denovoSkin™

CUTISS announces results from Phase 2 clinical trials for denovoSkin™ in adolescent and adult burn patients, and Phase 1 in children Phase 2 clinical trial reaches efficacy endpoint with high statistical significance for lead product denovoSkin™ in adult and adolescent burn patients. Phase 1 clinical trial of denovoSkin™ is completed with 5-year follow up demonstrating …

CUTISS announces positive Phase 2 clinical trial results for denovoSkin™ Read More »

Case report: Youngest patient ever treated with denovoSkin – a neonatal case

The paper published in Burns Open has presented the case of a four day-old neonate suffering from life threatening burns, involving 40% total body surface area burn. The patient received 260 cm2 of denovoSkin, covering 20% TBSA, as part of a clinical trial sub-study in Italy. The management of such cases represents an unprecedented challenge. …

Case report: Youngest patient ever treated with denovoSkin – a neonatal case Read More »

Fierce Biotech interview

The leading industry media Fierce Biotech reported on the news that CUTISS sent human skin cells into space, for advanced R&D testing on the International Space Station. Our Chief Innovation Officer Vincent Ronfard explained in his interview the reasons for conducting such experiments and what we hope to achieve. The initial round of experiments will …

Fierce Biotech interview Read More »

Advanced testing of human skin cells on the International Space Station to push the boundaries of innovation in regenerative medicine

As part of the company’s R&D in regenerative medicine, CUTISS will observe the effects of space on skin cells and tissue culture. Research implications towards human safety in space travel and new discoveries in regenerative medicine and tissue engineering on Earth. Four-week mission conducted in collaboration with SpacePharma which specializes in space-based experiments and micro-lab …

Advanced testing of human skin cells on the International Space Station to push the boundaries of innovation in regenerative medicine Read More »

Scroll to Top

Newsletter

Would you like to contact us as a journalist?

©WyssZurich

This website uses cookies to ensure you get the best experience on our website.